Evotec licenses Ncardia’s disease modeling patents

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: License, Patent, Stem cell

Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.

Ncardia – which was established in September 2017 following the merger of Pluriomics and Axiogenesis – provides standardized, validated induced pluripotent stem cell (iPSC)​ assays for safety, phenotypic screening, and disease modeling.

The company’s product portfolio encompasses a panel of hiPSC derived cryopreserved cardiomyocytes and neurons. It also delivers the CardioPlate product line of quality controlled ready to use assay plates.

The agreement – financial terms of which were not disclosed – is the second for Ncardia in the past two months. In October, the company announced a license agreement with Roche, Ncardia’s first pharmaceutical partner.

As part of the agreement, Roche has a worldwide license to Ncardia’s disease modeling patents to further discovery and development of novel drug candidates.

The company also completed a €10.5m ($12.42) Series B financing round in November.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Follow us


View more